Stanford University
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Inclusion Criteria: * Capable to provide informed consent * Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen. * Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched. Exclusion Criteria: * Pregnant or breastfeeding woman * Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.) * Diagnosis of glucose…
Topical insulin 100 U/ml, 1 drop per day
Topical insulin 500 U/ml, 1 drop per day
1 drop of low dose insulin twice daily.
1 drop of high dose insulin twice daily
1 drop of low dose insulin three times daily.
1 drop of high dose insulin three times daily.
Arctuva estimate
Verify or correct the compensation shown for this listing.